Recombinant Adeno-Associated Virus for the Generation of Autologous, Gene-Modified Tumor Vaccines: Evidence for a High Transduction Efficiency into Primary Epithelial Cancer Cells
- 1 May 1998
- journal article
- research article
- Published by Mary Ann Liebert Inc in Human Gene Therapy
- Vol. 9 (7) , 1049-1059
- https://doi.org/10.1089/hum.1998.9.7-1049
Abstract
To explore the potential of recombinant vectors based on recombinant adeno-associated virus (rAAV) for cancer vaccination, we investigated the transduction efficiency of rAAV into cancer cells ex vivo. Infection of human epithelial cancer cell lines with rAAV carrying reporter genes encoding β-galactosidase (rAAV/LacZ) or luciferase (rAAV/Luc) resulted in high levels of reporter gene expression (>90% positive cells). In marked contrast, rAAV poorly transduced all murine tumor cell lines, as well as human hematopoietic cell lines. Either irradiation or adenovirus infection of tumor cells prior to rAAV infection induced a 10- to 100-fold increase of reporter gene expression. To determine the transduction efficiency of rAAV into primary cancer cells, freshly isolated, irradiated tumor cells from malignant melanoma and ovarian carcinoma patients were infected with rAAV/Luc, resulting in up to 6.9-fold higher levels of gene expression than in a HeLa tumor cell line. Time course experiments with freshly isolated tumor cells infected with rAAV/Luc showed maximal levels of luciferase expression between days 3 and 9 posttransduction. Simultaneous infection of primary tumor cells with up to three rAAV vectors containing genes encoding the immunostimulatory proteins B7-2 (CD86), p35 subunit of IL-12, and p40 subunit of IL-12 resulted in high expression of B7-2 in more than 90% of the tumor cells and in the secretion of high levels of IL-12. Taken together, our results demonstrate that rAAV efficiently transduces freshly isolated human, epithelial tumor cells and might therefore be a potent tool to produce improved, gene-modified cancer vaccines. Highly efficient gene transfer into freshly isolated primary melanoma cells and primary ovarian carcinoma cells was achieved with recombinant AAV particles. Optimal transduction was obtained when cells were exposed to irradiation or adenovirus superinfection. Simultaneous transduction with three different AAV vectors was possible without significant loss of efficiency. High levels of foreign gene expression were observed over a period of 9 days.Keywords
This publication has 37 references indexed in Scilit:
- Gene transfer of costimulatory molecules B7–1 and B7–2 into human multiple myeloma cells by recombinant adeno-associated virus enhances the cytolytic T cell responseGene Therapy, 1997
- Quantitative Analysis of the Packaging Capacity of Recombinant Adeno-Associated VirusHuman Gene Therapy, 1996
- Coexpression of Interleukin-4 and B7.1 in Murine Tumor Cells Leads to Improved Tumor Rejection and Vaccine Effect Compared to Single Gene Transfectants and a Classical AdjuvantHuman Gene Therapy, 1996
- Cell Lines for the Production of Recombinant Adeno-Associated VirusHuman Gene Therapy, 1995
- Tumor cells cotransfected with interleukin‐7 and B7.1 genes induce CD25 and CD28 on tumor‐infiltrating T lymphocytes and are strong vaccinesEuropean Journal of Immunology, 1995
- Major histocompatibility complex class II+B7-1+ tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice.The Journal of Experimental Medicine, 1995
- Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brainNature Genetics, 1994
- Suppression of human alpha-globin gene expression mediated by the recombinant adeno-associated virus 2-based antisense vectors.The Journal of Experimental Medicine, 1994
- Immunotherapy with cytokine gene-transduced tumor cellsCurrent Opinion in Oncology, 1992
- Adeno-associated virus vectorsCurrent Opinion in Biotechnology, 1992